Nutriband Inc. Warrant (NTRBW) Stock Price

NTRBWStock

$0.50−1.71%52W

Market Cap—

P/E—

PEG Ratio—

Div yield—

Beta2.75

NTRBW Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-73.92%

Price vs S&P 500 (4W)-45.00%

VGM Score35.61

Industry Peers — Orthopedic & Prosthetic Devices(33)

Symbol	Value Score	Growth Score	Momentum Score	Price
NTRBWNutriband Inc. Warrant	—	—	D	$0.50
ISRGIntuitive Surgical Inc.	D	B	D	$371.84
EWEdwards Lifesciences Corp	D	C	B	$90.87
STESTERIS plc	C	B	C	$236.44
ZBHZimmer Biomet Holdings, Inc.	B	C	C	$100.24
SNNSmith & Nephew plc	B	C	D	$29.22
ALGNAlign Technology Inc	B	D	C	$159.61
MSAMine Safety Incorporated	C	C	C	$187.69
ESTAEstablishment Labs Holdings Inc.	F	A	C	$72.15
ENOVEnovis Corporation	B	D	C	$25.58
CDRECadre Holdings, Inc.	C	C	C	$31.39
AVNSAvanos Medical, Inc.	B	D	C	$24.99
AVRAnteris Technologies Global Corp. Common Stock	F	D	B	$8.89
SMTISanara MedTech Inc. Common Stock	D	C	B	$34.67
ZJYLJIN MEDICAL INTERNATIONAL LTD. Class A Ordinary Shares	B	D	C	$2.77
CNXUConexeu Sciences Inc. Common Stock	—	—	F	$7.55
INGNInogen Inc	B	D	D	$5.54
LAKELakeland Industries Inc	B	D	C	$11.52
SPAISafe Pro Group Inc. Common Stock	F	C	B	$5.25
NTRBNutriband Inc. Common Stock	F	D	B	$4.83
MYOMyomo Inc.	C	B	B	$1.48
COCHEnvoy Medical, Inc. Class A Common Stock	D	D	C	$0.75
APTAlpha Pro Tech, Ltd.	A	D	C	$5.36
MLSSMilestone Scientific, Inc. Common Stock	D	D	B	$0.48
LFWDLifeward Ltd. Ordinary Shares	B	D	C	$7.39
RGNTRegentis Biomaterials Ltd.	—	—	C	$2.09
HSCSHeartSciences Inc. Common Stock	F	F	B	$3.00
CUPRCuprina Holdings (Cayman) Limited Class A Ordinary Shares	—	D	C	$2.92
CLGNCollPlant Biotechnologies Ltd Ordinary Shares	C	F	F	$0.29
FEEDENvue Medical, Inc. Common Stock	A	F	F	$0.39
BBLGBone Biologics Corp Common Stock	—	—	F	$0.60
BBLGWBone Biologics Corp Warrants	—	—	D	$8.24
COCHWEnvoy Medical, Inc Warrant	—	—	F	$0.04
HSCSWHeartSciences Inc. Warrant	—	—	F	$0.04

About Nutriband Inc. Warrant

Nutriband Inc develops transdermal pharmaceutical products designed to prevent opioid abuse, diversion, and misuse. The company's proprietary AVERSA technology incorporates aversive agents into transdermal formulations to discourage drug abuse. Revenue is primarily generated through the sale of consumer transdermal and coated pharmaceutical products.